# Saizen in Intra-uterine Growth Retardation

> **NCT01400698** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 91 (actual)

## Conditions studied

- Children Born With Serious Intra-uterine Growth Retardation

## Interventions

- **DRUG:** Saizen® A
- **DRUG:** Saizen® B
- **OTHER:** Observation only

## Key facts

- **NCT ID:** NCT01400698
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2013-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01400698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01400698, "Saizen in Intra-uterine Growth Retardation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01400698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*